FARD (RaDiCo Cohort) (RaDiCo-FARD)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

900 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-03-07

Study Completion Date

2027-03-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to conduct a prospective assessment of the individual Burden of 9 rare skin diseases to assess disability in the broadest sense of the term (psychological, social, economic and physical) for patients and/or families.

Two types of indicators will be used to reach this objective :

1. an individual burden score calculated based on a burden questionnaire created specifically, approved and designed to understand the tendency to changes in care and lifestyles. The burden questionnaire should be used by patients and/or their family themselves in self-assessment.
2. a descriptive analysis of all resources (medical and non-medical) used by the family unit to manage the disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Immune Tolerance and Capacity for Wound Healing of Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NCT01874769

Recessive Dystrophic Epidermolysis Bullosa

COMPLETED

Characterization of the Cytokine Profile and the Microbiome in Darier's Disease

NCT06614777

Darier Disease

RECRUITING NA

A Pilot Cohort Study of Risk Factors and Novel Methods of Skin Lesion Assessments in Adults With Atopic Dermatitis, Alopecia Areata, Psoriasis or Vitiligo

NCT06319781

Alopecia Areata Vitiligo Atopic Dermatitis +1 more

RECRUITING

Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa

NCT01019148

Epidermolysis Bullosa Dystrophica

RECRUITING

Rationalization of the Treatment Pathway of Patient Suffering From Rare Skin Disease With Telemedicine

NCT02465476

Skin Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inherited Epidermolysis Bullosa Ichthyosis Ectodermal Dysplasia Incontinentia Pigmenti Neurofibromatosis Type 1 Albinism Pemphigus Mucous Membrane Pemphigoid Palmoplantar Keratoderma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* adults or children with a confirmed diagnosis of one of the 9 following rare skin disease: Inherited epidermolysis bullosa, Ichthyosis, Ectodermal dysplasia, Incontinetia Pigmenti, Neurofibromatosis type 1, Albinism, Pemphigus, Mucous membrane pemphigoid or Palmoplantar keratoderma.
* prevalent or incident and followed in one the reference/competence centers of the FIMARAD healthcare network,
* able to understand a survey (for child, survey should be understood by parents),
* having given their signed consent to participate to the cohort RaDiCo-FARD (parents' consent for child).

* Patients, for whom regular care follow-up is not feasible with the FIMARAD healthcare network sites,
* Unconfirmed diagnosis (according to criteria for each disease),
* Patients (and/or parents) not able to understand a survey
* Patients (and/or parents) not having given their signed consent to participate to the study

Eligible Sex

ALL

Accepts Healthy Volunteers

No